Genentech, a member of the Roche Group
Rozlytrek is a prescription medicine that is used to treat adults with non-small cell lung cancer that has spread to other parts of the body and is caused by an abnormal ROS1 gene.
The drug is for adults and children 12 years and older with solid tumors that are caused by certain abnormal NTRK genes, have spread or if surgery to remove their cancer is likely to cause severe complications if there is no satisfactory alternative treatment option or cancer has grown or spread on other treatment.
Rozlytrek was approved through faster FDA review process that was based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long that response lasted.
Common side effects of the medication include tiredness, constipation, change in taste, swelling, dizziness, diarrhea, nausea, abnormal touch sensation, shortness of breath, muscle pain, confusion, mental status changes, memory problems, hallucinations, weight gain, cough, vomiting, fever, joint pain and vision changes.
Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs